IMO I also understand he wants to see the applications of Zantrene maximised to deliver significant benefit for patients. I don’t think he would want to see an acquirer rest on their laurels in terms of FTO. The earlier ramp up occurs of indications in the clinic the better.
I think patients would wish they had more diagnostic, prognostic and treatment options available yesterday. This I definitely say personal experience.
RAC media coverage, page-1377
-
- There are more pages in this discussion • 920 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.67 |
Change
-0.020(1.18%) |
Mkt cap ! $282.9M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.64 | $48.19K | 28.95K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 8279 | $1.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 731 | 1 |
View Market Depth
| Last trade - 14.58pm 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |